A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

About the trial

Sponsor

Eli Lilly and Company (with AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd.)

Tested

LY3819253 (drug), LY3832479 (drug), LY3853113 (drug), Placebo (drug)

Dates

Started 2020-06-17; completion 2023-02-21

Results posted

Yes

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment b…

From ClinicalTrials.gov, last updated 2024-04-11. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $77,958 in research payments for this study in 2025 (2 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.